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ABSTRACT
Aim To determine whether cytisine was at least as effective as varenicline in supporting smoking abstinence for
≥ 6 months in New Zealand indigenous Māori or whānau (extended-family) of Māori, given the high smoking prevalence
in this population. Design Pragmatic, open-label, randomized, community-based non-inferiority trial. Setting Bay of
Plenty, Tokoroa and Lakes District Health Board regions of New Zealand. Participants Adult daily smokers who identi-
fied as Māori or whānau of Māori, were motivated to quit in the next 2 weeks, were aged ≥ 18 years and were eligible for
subsidized varenicline. Recruitment used multi-media advertising. Interventions A total of 679 people were randomly
assigned (1 : 1) to receive a prescription for 12 weeks of cytisine or varenicline, plus low-intensity cessation behavioural
support from the prescribing doctor and community stop-smoking services or a research assistant. Day 5 of treatment
was the designated quit date. Measurements The primary outcome was carbon monoxide-verified continuous
abstinence at 6 months, analysed as intention-to-treat (with multiple imputation for missing data). Secondary outcomes
measured at 1, 3, 6 and 12 months post-quit date included: self-reported continuous abstinence, 7-day point prevalence
abstinence, cigarettes per day, time to (re)lapse, adverse events, treatment adherence/compliance and acceptability,
nicotine withdrawal/urge to smoke and health-care utilization/health-related quality of life. Findings Verified continu-
ous abstinence rates at 6 months post-quit date were 12.1% (41 of 337) for cytisine versus 7.9% (27 of 342)
for varenicline [risk difference 4.29%, 95% confidence interval (CI) = –0.22 to 8.79; relative risk 1.55; 95% CI = 0.97–
2.46]. Sensitivity analyses confirmed that the findings were robust. Self-reported adverse events over 6 months occurred
significantly more frequently in the varenicline group (cytisine: 313 events in 111 participants; varenicline: 509 events in
138 participants, incidence rate ratio 0.56, 95% CI = 0.49–0.65, P< 0.001) compared with the cytisine group. Common
adverse events were headache, nausea and difficulty sleeping. Conclusion A randomized controlled trial found that
cytisine was at least as effective as varenicline at supporting smoking abstinence in New Zealand indigenous Māori or
whānau (extended-family) of Māori, with significantly fewer adverse events.
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Combination nicotine replacement therapy (NRT) and
varenicline are currently the most effective smoking
cessation medications available, and are approved for use
by many of the world’s regulatory authorities [including
the European Medicines Agency (EMA), the UK Medicines
and Healthcare Products Regulatory Agency (MHPRA)
and the US Food and Drug Administration (FDA)]. A less
well-known medication is cytisine, a plant-based alkaloid
which was first authorized for use as a smoking cessation
medication in Bulgaria in 1964 [1]. Cytisine is currently
available over-the-counter and/or on prescription as a
smoking cessation treatment in 18 central/eastern
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European countries, but does not have regulatory approval
for use in the United Kingdom, western Europe, the United
States or countries that follow the regulatory approval pro-
cesses of these nations [for example, New Zealand (NZ)]
[2]. However, cytisine has been sold in Canada as an
over-the-counter herbal product for smoking cessation
since 2017 [1].
Like varenicline, cytisine is structurally similar to nico-
tine and acts as a partial agonist at nicotinic acetylcholine
receptors [1,3], although the two medications have differ-
ent half-lives (cytisine: 4.8 hours [4]; varenicline: 17 hours
[5]) and dosing regimens. Cytisine has been found in
clinical trials to be superior to both placebo [1,6–9] and
nicotine replacement therapy (NRT) [10] at supporting
smoking abstinence, with mild and self-limiting adverse
events reported [1,6–10]. No trials have yet been published
directly comparing cytisine with varenicline, despite
observed effect sizes in a trial comparing cytisine to NRT
[10] being similar to those in a trial comparing varenicline
to NRT [11]. A major advantage of cytisine over
varenicline is the current large price difference between
the two drugs in markets where currently approved [12],
the much lower cost per quality-adjusted life-years for
cytisine [13] and modelling suggesting that cytisine may
be considerably more cost-effective than varenicline
[14,15]. Furthermore, as a natural product, cytisine may
be appealing to certain populations, e.g. indigenous people
who smoke [16].
We aimed to investigate whether cytisine was at least as
effective as varenicline in supporting smoking cessation
among the indigenous Māori people of NZ [17], who com-
prise 16.5% of the NZ population [18]. In 2018/19 Māori
had a high prevalence of daily smoking (30.9%) compared
with the general population (12.5%) [19]. NZ smoking
cessation trials indicate that Māori are just as likely to quit
smoking as non-Māori [10,20]. We hypothesized that
12weeks of cytisine plus low-intensity behavioural support
(BHS) would be at least as effective as 12 weeks of
varenicline plus low-intensity BHS for smoking cessation
at 6 months post-quit date.
METHODS
Study design
We undertook a parallel-group, randomized, controlled,
pragmatic non-inferiority trial. A pragmatic design was
chosen to ensure that the study findings were as generaliz-
able as possible, reflecting real-world access to varenicline
(and probably cytisine, if it receives marketing approval in
NZ). The trial was conducted and monitored according to
good clinical practice guidelines and is reported with
fidelity to the final version of the protocol and statistical
analysis plan. An earlier version of the protocol has been
published [17]. Key differences between the published
protocol and the final protocol relate to expansion of the re-
cruitment region and use ofmultiple imputation analysis to
account formissing data. The protocolwas approved by the
NZ Multi-Region Ethics Committee and the HRC Standing
Committee on Therapeutic Trials (SCOTT), which assesses
trials of newmedicines that require approval under Section
30 of the Medicines Act 1981. The trial was undertaken in
the LakesDistrictHealth Board region ofNZ, then expanded
to the Bay of Plenty and Tokoroa regions.
Participants
Participants were recruited via multi-media advertising
and promotion by community-based smoking cessation
services and health professionals. Advertisements directed
potential participants to register via the study website
(and be called back by a researcher) or to call/text a re-
searcher directly. Registered participants were provided
with further trial information and assessed for eligibility.
All participants provided verbal consent. Inclusion criteria
were: self-identified as Māori orwhānau of Māori (including
people who are not themselves Māori by whakapapa
(genealogy) but live in a Māori whānau, such as in a
household by marriage); aged ≥ 18 years; smoked tobacco
daily; motivated to quit in the next 2 weeks; eligible
for government-subsidized varenicline via the special
authority process; able to provide verbal consent; and had
daily access to a mobile phone/internet. Exclusion criteria
were: pregnant/breastfeeding; currently using smoking
cessation medication (including e-cigarettes); enrolled in
another cessation programme/study; had used varenicline
or cytisine in the previous 12 months; had a known
hypersensitivity to cytisine or varenicline; self-reported
moderate/severe renal impairment; treatment for active/
latent tuberculosis; experienced a heart attack, stroke or
severe angina within the previous 2 weeks; uncontrolled
high blood pressure (> 150 mmHg systolic,
> 100 mmHg diastolic); and/or a history of seizures.
Randomization/masking
Eligible participants were randomly allocated (1 : 1) to
receive a prescription for a 12-week course of cytisine
(Tabex®) or varenicline (Champix®). Block randomization
was undertaken, with varying block sizes. The randomiza-
tion sequence was prepared by the trial statistician using R
and loaded into the REDCap database, which was then
accessed by the study doctor via a computer at the point
of randomization. The trial was open-label, as participants
and researchers collecting outcome data were not masked
to treatment allocation. Although a double-blind trial
would have been ideal, participants were not blinded given
the different dosing regimens for the medications and their
different appearance. Two of the six lead investigators
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(M.V., S.P.) were blinded to treatment allocation until after
data lock and analysis. Three lead investigators (N.W., C.B.,
J.B.) were unblinded when assessing and assigning causal-
ity for serious adverse events, and the trial statistician was
required to create unblinded reports for the trial Data
Safety Monitoring Committee (DSMC).
Procedures
Participants were advised to visit their preferred commu-
nity pharmacy for dispensing of their allocated medicine.
Prescriptionswere uploaded by the study doctor to a secure
website for pharmacists to access. In line with current
access to varenicline in NZ, pharmacists dispensed
allocated treatment in three allotments over 8 weeks.
Access to study medications was free for participants.
To ensure comparability, both groups were asked to
reduce their smoking as much or as often as necessary or
desired over the first 4 days of treatment so that they were
smoke-free by day 5 (‘quit date’), and to follow the dosing
regimen for their allocated product. The quit date at day
5 was the same for both medications and was in line with
standard instructions for use of cytisine (note: inNZ, packet
instructions for varenicline suggest that users adopt a flex-
ible quit date between 8 and 35 days, and do not explicitly
promote a cut-down to quit process). The two study treat-
ments have very different dosing regimens. For cytisine, the
standard 25-day dosing regimen was followed: days 1–3:
one tablet (1.5 mg) every 2 hours through the waking
day (six tablets/day); days 4–12: one tablet every 2.5 hours
(five tablets/day); days 13–16: one tablet every 3 hours
(four tablets/day); days 17–20: one tablet every 4–5 hours
(three tablets/day); and days 21–25: one tablet every
6 hours (two tablets/day). A maintenance dose of cystine
was added for day 26 to week 12 (one tablet every 6 hours:
two tablets/day) to match the treatment duration of
varenicline. This choice was supported by repeat-dose
pharmacokinetic data and modelling provided by Achieve
Life Sciences, demonstrating adequate steady-state plasma
concentrations of cytisine during the maintenance period.
For varenicline, the dosing regimen was according to the
approved recommendations for Champix: days 1–3: one
tablet (0.5mg) per day; days 4–7: one tablet (0.5mg) twice
a day; and day 8–week 12: one tablet (1.0 mg) twice a day.
A full prescription consisted of 219 tablets for cytisine and
165 tablets for varenicline.
Participants were offered smoking cessation BHS, to
replicate support available in NZ when cessation medica-
tions are prescribed by a medical doctor; namely: (1) brief
advice delivered by the study doctor immediately after
writing the prescription (post-randomization) and (2) refer-
ral to community-based cessation services for additional
free BHS (delivered through telephone, text, face-to-face,
or group counselling). If participants refused referral, they
were offered 6 weeks of BHS telephone calls (one call per
week, 10–15 minutes per call) delivered by the trial re-
search assistants. This support encouraged positive en-
gagement to ensure that participation in the study
aligned with their tūmanako (aspirations).
The majority of outcome data were collected by
telephone interview at baseline, then 1, 3 and 6 months
(and 12 months in an early cohort of participants)
post-quit date. Adverse event (AE) data were collected via
self-report at each follow-up call, via a prompted
participant-completed web-based AE diary, and/or re-
ported by community pharmacists, general practitioners
and/or community-based smoking cessation providers.
Verification of smoking abstinence at 6 and 12 months
post-quit was undertaken face-to-face at a site convenient
to the participant.
Outcomes
Baseline data included age, gender, iwi (tribe), connected-
ness to iwi and education (as a proxy for socio-economic
status). Residential address was also used to determine
neighbourhood socio-economic status based on the NZ
Index of Multiple Deprivation (NZDep) [21]. Other baseline
data included: smoking history; cigarette dependence
[FagerströmTest of Cigarette Dependence (FTCD); score be-
tween 1 and 10, with scores > 5 indicating high cigarette
dependence and ≤ 5 indicating low dependence] [22,23];
tobacco withdrawal symptoms and urge to smoke [mood
and physical symptoms scale (MPSS) for seven symptoms:
1 = not at all, 5 = extremely, with a total score of 5–25,
urge to smoke scored 0–10: the higher the score the
greater the urge] [24]; motivation to quit (1 = very low,
5 = very high); alcohol use [Alcohol Use Disorders Identifi-
cation Test (AUDIT-C), scale of 0–12, the higher the score
the greater the risk of alcohol dependence] [25]; and
health-related quality of life using the EQ-5D instrument
(https://euroqol.org/); health-care utilization [26]; and
concomitant medication.
The primary outcome was continuous smoking absti-
nence 6 months post-quit (self-reported abstinence since
quit date, allowing ≤ 5 cigarettes in total but none in the
last week [27]), analysed as intention-to-treat (ITT) (with
multiple imputation for missing data). Abstinence was
verified by a researcher or community-based cessation
provider, using standardized exhaled carbon monoxide
(CO) measurement with a Bedfont Smokerlyzer (Bedfont
Scientific Ltd, Kent, UK), with a reading of ≤ 9 parts per
million (p.p.m.) signifying abstinence [27,28].
Secondary outcomes included: self-reported treatment
adherence (picking up their prescription from the phar-
macy) and treatment compliance (taking their assigned
medication); tobacco withdrawal symptoms and urge
[24]; self-reported continuous abstinence; 7-day point
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prevalence abstinence (no cigarettes, not a single puff, in
the previous 7 days) [27]; time to first cigarette smoked
from the quit date, even a single puff (lapse); time to first
relapse (time to smoking more than five cigarettes a day
for 3 or more days in a row); number of cigarettes smoked
per day; product acceptability at end of treatment; other
cessation support used during the trial; concomitant
medication; health-related quality of life (3 and 6 months);
and health-care utilization [26]. AEs were coded using the
Medical Dictionary for Regulatory Activities (MedDRA).
Serious AEs (SAEs) were classified by three authors and
the study doctor as non-serious or serious (death, life-
threatening, hospitalization, persistent or sustained disabil-
ity/incapacity, congenital abnormality/birth defect, signifi-
cant medical event). Likelihood of causality was assessed
using the World Health Organization (WHO) Standardized
Case Causality Assessment Tool (certain, probable/likely,
possible, unlikely, conditional/unclassified, unassessable/
unclassifiable) [29].
Statistical analysis
A planned sample size of 2140 people (1070 per group)
assumed 28% loss to follow-up [10] and 90% power at
the one-sided significance level of 2.5% to detect a
non-inferiority margin of 10% between the two groups at
6 months. The 6 month quit rate was estimated to be
22% in the cytisine group, based on data from a national
NZ Quitline trial (n = 1310) [10]. A 6-month quit rate of
28% was reported in a varenicline trial (n = 714) under-
taken in participants with stable cardiovascular disease
[30]; however, we chose to be more conservative, and as-
sumed a 25% quit rate given the pragmatic
community-based nature of our trial.
Analyses using SAS version 9.4 followed a pre-specified
plan, and the trial had an independent DSMC.
Non-inferiority for the primary outcome was evaluated
by observing whether the lower bound of the two-sided
95% confidence intervals (CI) for risk difference in quit
rates between the groups was above the non-inferiority
limit of minus 10. This margin of error was chosen as it
was the smallest value that is clinically relevant [31]. If
non-inferiority was evident, we planned assessment as to
whether cytisine had superior effectiveness to varenicline,
using the same approach but comparing to a zero differ-
ence. The primary analyses were carried out on ITT basis,
withmultiple imputation analysis performed to account for
missing data using the fully conditional specification logis-
tic regression method (data were assumed to be missing at
random). Fifty multiple imputed data sets were created,
and the imputation model included baseline age, sex,
NZDep [21] and treatment group. The imputed data sets
were analysed using log-binomial regression and combined
to output one inference. Quit rates, relative risk and risk
difference were calculated.
To check robustness of the results various sensitivity
analyses were performed. Analyses addressing the impact
of different limits for CO measurements (i.e. at ≤ 3,
≤ 5 and ≤ 8 p.p.m.) were undertaken. Groups were com-
pared using χ2 tests for the following analyses: complete
case analysis, assuming that participants with missing
smoking status datawere smokers, and per-protocol analy-
sis excluded participants with major protocol violations
(e.g. death, pregnancy, withdrawals, loss to follow-up,
non-adherence, non-compliance). Self-reported adherence
was defined as having collected all 12weeks’ studymedica-
tion from a pharmacy. Self-reported medication compli-
ance was defined as having collected all 12 weeks’ study
medication from a pharmacy and taken most or all of their
tablets. A second measure of medication compliance was
defined as having taken ≥ 80% of study medication
3 months post-quit date.
In pre-specified subgroup analyses, the consistency of
effects was assessed in the primary outcome for age
(< 40/≥ 40 years), sex and education (< 12 years of
schooling or no qualification/≥ 12 years of schooling), type
of cigarettes smoked (factory-made only/roll-your-own
only/both), extent of cigarette dependence (Fagerström
score: low, high) and AUDIT-C score (low/high: high =
AUDIT-C score ≥ 4 for men and ≥ 3 for women), using tests
for heterogeneity. We assessed change from baseline in
symptoms of tobacco withdrawal symptoms (for
abstainers) and number of cigarettes per day (for smokers)
over time using repeated-measures mixed models adjusted
for baseline value. Kaplan–Meier curves, the log-rank test
and Cox proportional hazards regression analysis were
used to measure smoking relapse (time to first lapse and re-
lapse from quit date) in those with data available.
Role of the funding source
This research was supported by a contract from the Health
Research Council of NZ. The funder had no role in
development of the study design, data collection, analysis
and interpretation or writing of the publication. The corre-
sponding author had full access to all data in the study and
had final responsibility for the decision to submit for
publication.
Data sharing
Indigenous data sovereignty is managed by the RAUORA
Māori (Kaitiaki) governance group, with support from
members of the NIHI Māori Research Advisory Committee.
Requests for access to the data or study documents will be
considered by these groups where the proposed use aligns
with public good purposes, does not conflict with other
2850 Natalie Walker et al.
© 2021 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction, 116, 2847–2858
requests or planned use by the study authors, and the re-
questor is willing to sign a data access agreement. Contact
is through the corresponding author.
RESULTS
The first randomization occurred on 18 September 2017,
and the last follow-up occurred on 10 October 2019. Of
1105 people assessed, 679 were eligible and randomized,
337 in the cytisine group and 342 in the varenicline group
(Fig. 1). This sample size was less than planned: we
experienced delays in obtaining ethics and regulatory ap-
provals and recruitmentwas slower than anticipated, so re-
cruitment could not continuewithout additional resources.
Twenty-three participants were excluded from the trial
because they did not want to use varenicline, but no one
was excluded because they did not want to use cytisine.
Nine participants allocated varenicline withdrew from the
study immediately after being randomized or by the first be-
havioural support call, compared to zero participants
allocated cytisine. Differential withdrawal was still evident
by 6 months: 31 (9%) participants in the cytisine group
Figure 1 Trial trofile: *not eligible for varenicline under special authority (n = 13), high risk/history of epilepsy (n = 5), outside study region (n = 5),
not Māori or whānau of Māori (n = 5), currently using smoking cessation medication (n = 3), non-daily smoker (n = 3), breastfeeding (n = 2), other
trial participant in household (n= 2), severe renal disease (n= 1), contraindication to varenicline (n= 1), did not want to use varenicline (n= 1). **Did
not want to use varenicline (n = 22), not eligible for varenicline under special authority (n = 11), high risk/history of epilepsy (n = 4), outside study
region (n = 3), contraindication to varenicline (n = 3), unstable hyperthyroidism (n = 3), currently using smoking cessation medication (n = 1),
breastfeeding (n = 1), no national health index number, which was required for the prescription (n = 1). aMissing: the number of participants who
were contacted but did not provide data (this includes a subset where data had not been handled in accordance with the protocol, which were there-
fore counted as missing). bLost to follow-up: the number of participants who could not be contacted at this follow-up time-point. cWithdrawn: the
number of participants who withdrew from the trial (no further data were available)
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withdrew, compared with 49 (14%) participants in the
varenicline group, primarily due to adverse events [66%
(35 of 53) of participants who provided a reason for with-
drawal]. Loss to follow-up at 6 months was 34% overall,
and similar in both groups (Fig. 1). Missing data ranged be-
tween 14 and 46%, depending on the variable and
time-point of measurement (this included a subset of data
at each time-point that had not been handled in accor-
dance with the protocol, which was, therefore, counted as
missing).
Baseline characteristics were evenly balanced between
treatment groups (Table 1, Supporting information,
Tables S1 and S2). Participants had a mean age of 43 years
[standard deviation (SD) = 11.9, range = 8–82], a strong
motivation to quit, and were predominantly women
(69.7%).
Cytisine was non-inferior to varenicline, but not clearly
superior: 6 month continuous abstinence rates were
12.1% (41 of 337) for cytisine versus 7.9% (27 of 342)
for varenicline (risk difference = 4.29; 95% CI = 0.22
to 8.79, risk ratio = 1.55; 95% CI = 0.97–2.46; Table 2).
Sensitivity (Table 2) and subgroup (Supporting
information, Table S3) analyses yielded results that were
consistent with the primary findings. Secondary cessation
outcomes at 3, 6 and 12months were also consistent with
the primary outcome (Table 2).
Overall, 96% of participants (225 of 234 with available
data) collected all or some of their 12-week prescription:
50% (117) collected all their medication, 27% (64) col-
lected only two of the three medication instalments and
19% (44) collected only the first medication allotment
(Supporting information, Table S4). No difference in medi-
cation collection was observed between the groups, even
when those lost to follow-up or withdrawn were assumed
to be non-adherent (Supporting information, Table S4). Of
the 117 participants with available data who said they
had collected their full prescription, 84 (72%) reported
that they took most or all of their study medication, with
no difference between groups (Supporting information,
Table S4).
Self-reportedAEs occurred less frequently in the cytisine
group (313 events in 111 participants) compared with the
varenicline group (509events in138 participants),with an
incidence rate ratio of 0.56, 95% CI = 0.49–0.65,
P < 0.001. The on-line participant diary was the most
common source of AE reporting (66%), followed by partic-
ipant interview (30%, Table 3). Forty-one per cent (128) of
AEs in the cytisine group were assessed as certain or prob-
ably/likely related to treatment, compared to 57% (290) in
the varenicline group (Table 3). Thirty-five SAEs were re-
ported (cytisine: 16 events in 16 participants; varenicline:
19 events in 17 participants), with none assessed as certain
or probably/likely related to treatment (Table 3, Supporting
information, Table S6).Two SAEs were assessed as possibly
related to treatment: one in the cytisine group (depression)
and one in the varenicline group (cholecystectomy). The
most frequently reported AEs in both groups were head-
ache, nausea, difficulty sleeping, vivid dreams, tiredness,
stomach-ache and dry mouth (Table 4).
Eighty-eight per cent (104 of 118) of participants
allocated cytisine stated at 3 months that they would rec-
ommend their allocated treatment to others to help them
quit smoking, compared to 74% (86 of 116) allocated
varenicline (P = 0.037). There were no between-group dif-
ferences for other secondary outcomes (Supporting
information).
DISCUSSION
Cytisine was at least as effective as varenicline for smoking
cessation among Māori and whānau of Māori who smoked
daily and were motivated to quit. These findings were







Female (n, %) 223 (66.2) 250 (73.1)
Male (n, %) 114 (33.8) 92 (26.9)
Age (years)
Mean (SD) 43.1 (11.9) 43.5 (11.8)
Ethnicity
New Zealand Māori (n,
%)
322 (95.5) 318 (93.0)
Whānau of Māori (n, %) 15 (4.5) 24 (7.0)
Neighbourhood deprivationa
1 Least deprived (n, %) 7 (2.1) 3 (0.9)
2 16 (4.7) 23 (6.7)
3 45 (13.4) 41 (12.0)
4 51 (15.1) 45 (13.2)
5 Most deprived (n, %) 218 (64.7) 230 (67.3)
Motivation to quitb n = 182 n = 210
Score ≥ 4 142 (78.0) 157 (74.8)
Median (IQR) 4.5 (4–5) 5 (3–5)
Cigarette dependencec n = 181 n = 207
Mean (SD) 5.2 (2.5) 5.2 (2.2)
Cigarettes per dayd n = 193 n = 220
Mean (SD) 15.5 (7.8) 15.5 (7.8)
Alcohol usee n = 179 n = 206
Female (mean, SD) 3.5 (3.3) 3.2 (3.0)
Male (mean, SD) 4.2 (3.6) 4.8 (3.3)
SD = standard deviation. IQR = interquartile range.
a
Based on the New
Zealand Index of Multiple Deprivation, which measures deprivation at the
neighbourhood level [21].
b
Measured on a scale of 1–5: 1 very low, 5 very
high.
c
Cigarette dependencemeasured using the FagerströmTest of Cigarette
Dependence [22,23], which is on a scale of 1–10, with scores> 5 indicating




Alcohol use was measured using the Al-
cohol Use Disorders Identification Test (AUDIT-C), on a scale of 0–12, where
the higher the score the greater the risk of alcohol dependence. For men, a
score ≥ 4 indicates an increased risk of hazardous drinking or alcohol depen-
dence, while in women it is a score of ≥ 3 [25].
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consistent among the various sensitivity and subgroup
analyses, and at 3, 6 and 12 months post-quit. Self-re-
ported AEs over 6 months occurred less frequently in the
cytisine group than in the varenicline group.
Self-reported medication adherence and compliance with
allocated treatment was similar between the groups, de-
spite the different dosing regimens.
A strength of this trial is its pragmatic design, reflecting
real-world access to varenicline in NZ (and potentially
cytisine, if granted a marketing authorization in NZ). The
trial highlights the benefits of working in partnership with
indigenous communities to support positive behaviour
change. Broad inclusion criteria and absence of incentive
payments to participants to improve medication adherence
and trial retention contribute to the generalizability of the
study findings to the ‘real world’. High participation by
Māori women (who have higher daily smoking rates than
Māori men: 33% versus 29%, respectively, in 2018/19)
[19] suggests strong motivation among this group to quit.
Medical exclusion criteria reflected themanufacturers’ pre-
cautions for use of cytisine and varenicline. We followed
the manufacturers’ recommended dosing regimens for
both medications, although this trial is the first, to our
knowledge, to use an extended cytisine treatment. This
prolonged treatment (which is approximately three times
longer than the recommended dosing regimen) could be
a driver of the observed treatment effect. The trial had high
internal validity: we controlled for selection bias by under-
taking computer randomization, and the doctor randomiz-
ing participants did not know what the next treatment
allocation was. The moderate level of medication adher-
ence and compliance reflects how these behaviours impact
upon smoking abstinence rates in the population, although
some performance bias may exist. On first impression, it ap-
pears that the more complex dosing regimen for cytisine
was not a barrier to use. However, the research assistants
interacting with participants reported (but did not formally
record) that for many participants the cytisine dosage reg-
imen was a barrier, but one that was mitigated by some
participants’ preference for cytisine and delivery of behav-
ioural support in the first 6 weeks of treatment (which
highlighted the importance of medication adherence and
compliance). Our use of ITT analysis gave a conservative
treatment effect. No one type of analysis is perfect to ad-
dress the biases arising from loss to follow-up, withdrawal
andmissing data in a trial of this nature.We chosemultiple
Table 3 Summary of all-cause adverse events.
Total adverse events and SAEs Cytisine n = 313 Varenicline n = 509
Source of adverse event and SAE reporting (n, %)a
On-line study diary 195 (62.3) 350 (68.8)
Study interview 102 (32.6) 141 (27.7)
Pharmacist 26 (8.3) 23 (4.5)
Otherb 16 (5.1) 26 (5.1)
Event type (n, %)
Adverse event 297 (94.9) 490 (96.3)
SAEs: death 0 0
SAEs: life-threateningc 0 1
SAEs: hospitalization 13 (4.2) 13 (2.6)
SAEs: congenital abnormalityd 0 1
SAEs: otherwise medically important 3 4
Causality assessment outcome for all adverse events and SAEs (n, %)g
Certain 98 (31.3) 223 (43.8)
Probable/likely 30 (9.6) 67 (13.2)
Possible 45 (14.4) 71 (13.9)
Unlikely 69 (22.0) 74 (14.5)
Conditional/unclassified 71 (22.7) 74 (14.5)
Unassessable/unclassifiable 0 0





Conditional/unclassified 12 (75.0) 17 (89.5)
Unassessable/unclassifiable 0 0
SAE = serious adverse event
a
Percentages do not tally as adverse events could be reported frommore than one source.
b
General practitioners (n = 1), commu-






Depression (cytisine group) and cholecystectomy (varenicline
group).
f
Dizziness, gall bladder inflammation, stroke (cytisine group) and cardiac arrest (varenicline group).
g
World Health Organization standardized case cau-
sality assessment tool [29].
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imputation as our preferred method to address this issue,
although we acknowledge that participants lost to
follow-up in smoking cessation trials are usually considered
to have resumed smoking. It is possible that some loss to
follow-up in this trial was due to adverse events, given that
participants withdrawing from the trial primarily cited side
effects as a reason. Thus, the assumption that participants
lost to follow-up have resumed smoking may not be valid
and would bias the effect sizes downwards [32]. However,
we still undertook sensitivity analyses with missing partic-
ipants assumed to be smoking and found a similar finding
to our primary analysis. We took a person-centred ap-
proach to AE reporting, with participants encouraged to
report ‘health events’ during and following treatment
using their own words. Finally, the observed self-reported
6-month continuous abstinence rate for cytisine (22%)
was consistent with our previous pragmatic trial, where
people calling the NZQuitline received a free 25-day course
of cytisine delivered at no cost to their home [10].
The study had a number of limitations. First, the smaller
than anticipated sample size is reflected in the wide CIs and
restricted our ability to undertake somecomparisons. Based
on the sample size obtained and the effect sizes observed,
the trial had just under 60% power, indicating an increased
likelihood of type 2 error. Secondly, higher than expected
loss to follow-up and missing data reduced the power of
the trial to test the hypothesis with precision and could
have resulted in under- or overestimation of treatment ef-
fects. To increase precision, we used multiple imputation
for missing data while adjusting for the uncertainty of the
missing data. To assess the robustness of findings for plausi-
ble alternative assumptions about themissing data, we un-
dertook sensitivity analyses that produced similar and
consistent results to the ITT analysis. Thirdly, treatment al-
location and delivery of behavioural support was not
blinded, so some reporting bias in favour of one treatment
or the other could have occurred. Fourthly,
treatment-related AEs may have reduced the likelihood of
quitting (i.e. some participants reported stopping medica-
tion because of AEs), or contributed to loss to follow-up or
the higher withdrawal rate seen in the varenicline group.
Early nausea during varenicline treatment may reduce ad-
herence and be associatedwith lower likelihood of smoking
cessation [33], so should be anticipated and managed in
people taking cytisine or varenicline. The lower incidence
of nausea in the cytisine group is probably due to cystine’s
slower potency at 5-HT3 receptors [34]. Fifthly, users of
non-cigarette tobacco productswere not excluded butwere
likely to be few, because smokeless tobacco and heat-
not-burn products were not available for sale in NZ prior
to March 2018. Sixthly, there may be some preference bias
in favour of cytisine because of its novelty (e.g. some partic-
ipantsmay have preferred cytisine over varenicline because
it was new, and they may have used varenicline in the past
and experienced an AE and/or did not quit), as well as its
‘natural’ status (important for many Māori, given their
strong connection with the land). We tried to mitigate this
bias by carefully describing the two medications to partici-
pants, to highlight their equipoise. However, as part of the
ethics process we had to explain in the participant informa-
tion sheet (see Supporting information) the source of both
medications (i.e. cytisine being plant-based and found in
several NZ plants, while varenicline was not plant-based,
but developed from cytisine), and present available AE in-
formation for the twomedications. Itwas evident that some
members of the study population preferred to be allocated
cytisine, given: (1) the numbers of potential participants
not wanting to engage in the trial if they could not have ac-
cess to this medication and (2) the differential withdrawal
noted in the first week post-randomization in those allo-
cated varenicline. Future cytisine trials should quantity
the potential effect of participants’ treatment preference
on the primary outcome by asking about preference at
baseline then stratifying the primary analyses accordingly
[35]. Finally, although AEs were self-reported, medically
reviewed and, like those reported in previous cytisine [1]
and varenicline research [8], the trial was neither large
enough nor long enough to assess occurrence of uncom-
mon AEs nor those with a long time to onset. Given the
above, it is important that the trial findings be considered
exploratory and subject to validation from additional trials
comparing cytisine to varenicline, and meta-analysis of
such trials.
Future analysis of the data set includes a
cost-effectiveness analysis to aid adoption decisions in NZ
and beyond, and post-hoc Bayesian analysis of the primary
outcome. Strategies to optimize medication adherence and
compliance for both medications to increase quitting suc-
cess should be investigated, plus further research on the ex-
tended treatment regimen for cytisine is justified. Research
should also focus upon the impact of cytisine on smoking
abstinence in other population groups who have high
smoking prevalence, such as people with psychiatric disor-
ders. Finally, further studies are needed to provide more
comprehensive data on the safety profile of cytisine, and
to examine approaches to maximizing its effectiveness,
such as use in combination with NRT and extended treat-
ment to prevent relapse.
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